Study #2020-0650
An Open-label Study using ASP-1929 Photoimmunotherapy in Combination with anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
MD Anderson Study Status
Not Accepting
Treatment Agent
200 mg Pembrolizumab, Combination Product: ASP-1929 PIT, 350 mg Cemiplimab
Description
Open-label study using ASP-1929 photoimmunotherapy in combination with anti-PD1 therapy in patients with recurrent or metastatic head and neck and squamous cell cancer or advanced or metastatic cutaneous squamous cell carcinoma.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma
Study phase:
Physician name:
Ann Gillenwater
Department:
Head & Neck Surgery
For general questions about clinical trials:
1-877-581-3446
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.